TY - JOUR
T1 - Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles identification of CYP2C haplotypes in healthy Nordic populations
AU - Pedersen, Rasmus S.
AU - Brasch-Andersen, Charlotte
AU - Sim, Sarah C.
AU - Bergmann, Troels K.
AU - Halling, J
AU - Petersen, MS
AU - Weihe, P
AU - Edvardsen, Helge
AU - Kristensen, Vessela N.
AU - Brosen, Kim
AU - Ingelman-Sundberg, Magnus
PY - 2010/12
Y1 - 2010/12
N2 - To determine the distribution of clinically important CYP2C genotypes and allele frequencies in healthy Nordic populations with special focus on linkage disequilibrium. A total of 896 healthy subjects from three Nordic populations (Danish, Faroese, and Norwegian) were genotyped for five frequent and clinically important CYP2C allelic variants: the defective CYP2C8*3, CYP2C9*2, CYP2C9*3, and CYP2C19*2 alleles, and the CYP2C19*17 allele that causes rapid drug metabolism. Linkage disequilibrium was evaluated and CYP2C haplotypes were inferred in the entire population. Ten CYP2C haplotypes were inferred, the most frequent of which (49%) was the CYP2C wildtype haplotype carrying CYP2C8*1, CYP2C9*1, and CYP2C19*1. The second most frequent haplotype (19%) is composed of CYP2C19*17, CYP2C8*1, and CYP2C9*1. This predicted haplotype accounts for 99.7% of the CYP2C19*17 alleles found in the 896 subjects. CYP2C19*17 is a frequent genetic variant in Nordic populations that exists in strong linkage disequilibrium with wildtype CYP2C8*1 and CYP2C9*1 alleles, which effectively makes it a determinant for a haplotype exhibiting an efficient CYP2C substrate metabolism.
AB - To determine the distribution of clinically important CYP2C genotypes and allele frequencies in healthy Nordic populations with special focus on linkage disequilibrium. A total of 896 healthy subjects from three Nordic populations (Danish, Faroese, and Norwegian) were genotyped for five frequent and clinically important CYP2C allelic variants: the defective CYP2C8*3, CYP2C9*2, CYP2C9*3, and CYP2C19*2 alleles, and the CYP2C19*17 allele that causes rapid drug metabolism. Linkage disequilibrium was evaluated and CYP2C haplotypes were inferred in the entire population. Ten CYP2C haplotypes were inferred, the most frequent of which (49%) was the CYP2C wildtype haplotype carrying CYP2C8*1, CYP2C9*1, and CYP2C19*1. The second most frequent haplotype (19%) is composed of CYP2C19*17, CYP2C8*1, and CYP2C9*1. This predicted haplotype accounts for 99.7% of the CYP2C19*17 alleles found in the 896 subjects. CYP2C19*17 is a frequent genetic variant in Nordic populations that exists in strong linkage disequilibrium with wildtype CYP2C8*1 and CYP2C9*1 alleles, which effectively makes it a determinant for a haplotype exhibiting an efficient CYP2C substrate metabolism.
KW - CYP2C haplotypes
KW - CYP2C1917
KW - Linkage disequilibrium
KW - Allele frequencies
KW - HUMAN DRUG-METABOLISM
KW - GENETIC POLYMORPHISMS
KW - CLINICAL-RELEVANCE
KW - CYTOCHROME P4502C9
KW - SUBFAMILY
KW - ESCITALOPRAM
KW - ASSOCIATION
KW - OMEPRAZOLE
KW - INHIBITORS
KW - VARIANT
UR - http://dx.doi.org/10.1007/s00228-010-0864-8
U2 - 10.1007/s00228-010-0864-8
DO - 10.1007/s00228-010-0864-8
M3 - Article
SN - 0031-6970
VL - 66
SP - 1199
EP - 1205
JO - European Journal of Clinical Pharmacology
JF - European Journal of Clinical Pharmacology
IS - 12
ER -